Clinical Trials
32 trialsNCT00092222 2026-06-05
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04133636 2026-06-05
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04722146 2026-06-05
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04923893 2026-06-05
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06152575 2026-06-05
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06158841 2026-06-05
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-06-05
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06577025 2026-06-05
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT01415752 2026-06-03
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT02112916 2026-06-03
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05519085 2026-06-03
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT05736419 2026-06-03
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05848687 2026-06-03
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT07623798 2026-06-03
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Not yet recruiting
NCT07624513 2026-06-03
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute
Phase 3 Not yet recruiting
NCT01371981 2026-06-02
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT03652064 2026-06-02
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT04915248 2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2 Recruiting
NCT05231629 2026-06-02
MASTER-2
University of Alabama at Birmingham
Phase 2 Recruiting
NCT07227311 2026-06-02
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Recruiting
NCT06918002 2026-06-01
ElLen
Intergroupe Francophone du Myelome
Phase 3 Recruiting
NCT07601100 2026-06-01
IsaIberVD
Dana-Farber Cancer Institute
Phase 1/2 Not yet recruiting
NCT07614360 2026-05-29
DREAMM-16
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT07609706 2026-05-27
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT00734877 2026-05-22
TT4B
University of Arkansas
Phase 3 Active not recruiting
NCT00869232 2026-05-22
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Active not recruiting
NCT07600151 2026-05-20
CONQUISTADOR
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Not yet recruiting
NCT07285239 2026-05-18
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT04566328 2026-05-15
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT07085728 2026-05-15
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05623020 2026-05-14
MagnetisMM-6
Pfizer
Phase 3 Recruiting